Mesoblast (ASX:MSB) reported encouraging real-world outcomes for its FDA-approved therapy Ryoncil (remestemcel-L-rknd) in children with steroid-refractory acute graft-versus-host disease.
Ryoncil, the first mesenchymal stromal cell product approved by the US Food and Drug Administration for any indication, has been commercially available since March 2025 for children aged two months and older.
Among the first 25 pediatric patients treated in real-world clinical settings, 21 children (84%) survived and completed the initial 28-day treatment regimen.
The four patients who did not complete the course had previously failed other therapies and succumbed to severe SR-aGvHD within 28 days.
Mesoblast noted that these early outcomes align with prior clinical trial data and emphasise the importance of initiating Ryoncil therapy promptly after steroid resistance to maximise survival chances.